Ciclopirox oral - BioTheryX

Drug Profile

Ciclopirox oral - BioTheryX

Alternative Names: BTX-10504; Ciclopirox olamine

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator BioTheryX
  • Developer BioTheryX; The Leukemia & Lymphoma Society; University Health Network
  • Class Antifungals; Pyridones; Small molecules
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 29 Apr 2016 No recent reports on development identified - Phase-I for Acute myeloid leukaemia, Multiple myeloma and Myelodysplastic syndromes (Second-line therapy or greater) in Canada (PO)
  • 02 Dec 2010 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top